首页> 外文会议>International Mass Spectrometry Conference >CHEMOMETRIC OPTIMIZATION OF UPLC-MS/MS ASSAY FOR CLINICAL DIAGNOSIS AND PHARMACOTHERAPY MONITORING OF PATIENTS WITH APRT DEFICIENCY
【24h】

CHEMOMETRIC OPTIMIZATION OF UPLC-MS/MS ASSAY FOR CLINICAL DIAGNOSIS AND PHARMACOTHERAPY MONITORING OF PATIENTS WITH APRT DEFICIENCY

机译:UPLC-MS / MS测定的化学计量优化对于APRT缺乏患者的临床诊断和药物疗法监测

获取原文

摘要

Patients with APRT deficiency have excessive renal excretion of 2,8-dihydroxyadenine (DHA), causing chronic kidney disease. Treatment with allopurinol or febuxostat reduces DHA excretion and kidney stones formation. A chemometric approach was used for optimization of a UPLC-MS/MS assay for simultaneous quantification of DHA, adenine biomarkers and the pharmacological agents in human urine and plasma for clinical diagnosis and pharmacotherapy monitoring.
机译:缺乏症的患者具有2,8-二羟基腺嘌呤(DHA)的肾脏排泄过多,导致慢性肾病。含有Allopurinol或Febuxostat的治疗可降低DHA排泄和肾结石形成。用于优化化学计量方法用于优化UPLC-MS / MS测定,用于同时定量DHA,腺嘌呤生物标志物和人尿液中的药理学药物和血浆中的临床诊断和药物治疗监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号